Literature DB >> 17332946

Treatment of CNS dissemination in systemic lymphoma.

B Gleissner1, M Chamberlain.   

Abstract

The frequency of central nervous system (CNS) dissemination in non-Hodgkin's lymphoma (NHL) varies and is dependent on NHL histology. More than 50% of patients with CNS involvement have advanced and progressive systemic disease. While CNS involvement at initial diagnosis may be treated curatively, treatment of CNS involvement in systemic relapsing or refractory lymphoma is challenging and most often palliative. Due to a paucity of randomized trials, treatment of lymphomatous metastases is not standardized. Nonetheless, treatment of LM entails administration of both CNS-directed and systemic chemotherapy that often includes high-dose chemotherapy regimens with stem cell support.

Entities:  

Mesh:

Year:  2007        PMID: 17332946     DOI: 10.1007/s11060-007-9353-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  64 in total

1.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

Authors:  M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

2.  Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment.

Authors:  J Ersbøll; H B Schultz; B L Thomsen; N Keiding; N I Nissen
Journal:  Scand J Haematol       Date:  1985-11

3.  Cerebrospinal fluid involvement in mantle cell lymphoma.

Authors:  Riccardo Valdez; Steven H Kroft; Charles W Ross; Bertram Schnitzer; Timothy P Singleton; LoAnn C Peterson; William G Finn
Journal:  Mod Pathol       Date:  2002-10       Impact factor: 7.842

4.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

Authors:  K van Besien; C S Ha; S Murphy; P McLaughlin; A Rodriguez; K Amin; A Forman; J Romaguera; F Hagemeister; A Younes; C Bachier; A Sarris; K S Sobocinski; J D Cox; F Cabanillas
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

5.  [Bilateral breast masses].

Authors:  C Brachet; J P Dufrane; M Van De Casseye; M Ost; L Debusscher
Journal:  Rev Med Brux       Date:  2000-06

6.  Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.

Authors:  C D Williams; R Pearce; G Taghipour; E S Green; T Philip; A H Goldstone
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

Authors:  P Feugier; J M Virion; H Tilly; C Haioun; G Marit; M Macro; D Bordessoule; C Recher; M Blanc; T Molina; P Lederlin; B Coiffier
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

8.  Is central nervous system prophylaxis necessary in ocular adnexal lymphoma?

Authors:  A Restrepo; L E Raez; G E Byrne; T Johnson; P Ossi; P Benedetto; K Hamilton; C C Whitcomb; P A Cassileth
Journal:  Crit Rev Oncog       Date:  1998

9.  Characteristic features of malignant lymphoma with central nervous system involvement.

Authors:  S Yoshida; K Morii; M Watanabe; T Saito
Journal:  Surg Neurol       Date:  2000-02

10.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates.

Authors:  W M Hryniuk; J R Bertino
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

View more
  12 in total

1.  Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.

Authors:  Kota Sato; Michihiro Uchiyama
Journal:  BMJ Case Rep       Date:  2012-01-23

2.  Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Authors:  Gandhi Damaj; Sarah Ivanoff; Diane Coso; Loïc Ysaebert; Sylvain Choquet; Caroline Houillier; Anne Parcelier; Wajed Abarah; Zora Marjanovic; Rémy Gressin; Reda Garidi; Momar Diouf; Anne-Claire Gac; Jehan Dupuis; Xavier Troussard; Franck Morschhauseur; Hervé Ghesquières; Carole Soussain
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

Review 3.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

4.  Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.

Authors:  Karin Oechsle; Victoria Lange-Brock; Andreas Kruell; Carsten Bokemeyer; Maike de Wit
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

Review 5.  Novel approaches to treating leptomeningeal metastases.

Authors:  Jai Grewal; Marlon Garzo Saria; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-28       Impact factor: 4.130

6.  A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Manuel Trias; Albert Grañena; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

7.  Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy.

Authors:  Lorenzo Falchi; Marco Gunnellini; Laura Franco; Patrizia Ferrazza; Stefano Ascani; Anna Marina Liberati
Journal:  J Neurooncol       Date:  2009-08-21       Impact factor: 4.130

8.  Dural MALT lymphoma with disseminated disease.

Authors:  Kelly Matmati; Nabil Matmati; Yusuf A Hannun; Zoran Rumboldt; Sunil Patel; John Lazarchick; Robert Stuart; Pierre Giglio
Journal:  Hematol Rep       Date:  2010-12-03

9.  [18F]fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma.

Authors:  Jennifer L Holter; Kristin Thorp; M Leann Smith; Katarzyna Kedzierska; Kar-Ming A Fung; George Chacko; Karen Swisher; Robert Epstein; Mary K Gumerlock
Journal:  Cancer Imaging       Date:  2011-09-24       Impact factor: 3.909

10.  Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma.

Authors:  Charanpreet Singh; Arjun Lakshman; Aditya Jandial; Sudha Sharma; Ram Nampoothiri; Gaurav Prakash; Pankaj Malhotra
Journal:  Turk J Haematol       Date:  2016-11-22       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.